Athens

• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fi … Pending
  2025-523660-21-00 5 hemophilia A
• A study that will check the safety, tolerability and effectiveness of the study drug (OMN6), as well as how the body responds to it after a … Pending
  2025-524200-29-00 4 Hospital-acquired bacterial pneumonia or ventilated-associated bacteri
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 5 Primary Progressive Multiple Sclerosis (PPMS)
• THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: TH … Pending
  2025-525006-37-00 5 Infection and sepsis
• A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending
  2025-525013-23-00 4 Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
• A Study to Evaluate a New Treatment Option for Helicobacter pylori Infection Compared to First Line Treatment. Pending
  2026-525291-26-00 5 Helicobacter Pylori Infection
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Par … Recruiting
  2025-520988-41-00 4 2026-05-15 Immunoglobulin G4 related Disease (IgG4-RD)
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i … Recruiting
  2024-511593-70-00 5 2026-04-27 Polyarticular-course juvenile idiopathic arthritis
• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) Recruiting
  2025-523229-16-00 4 2026-04-27 locally advanced basal cell carcinoma patients
• L19IL2/TNF in patients with basal cell carcinoma Recruiting
  2025-523230-77-00 4 2026-04-27 Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
• L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting
  2025-523231-19-00 4 2026-04-27 Cutaneous Squamous Cell Carcinoma
• A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). … Recruiting
  2025-520918-64-00 4 2026-04-24 Primary Antiphospholipid Syndrome (APS)
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A Study of Transition Regimens to KPL-387 Monotherapy in Participants with Well-Controlled Recurrent Pericarditis Recruiting
  2025-523234-66-00 4 2026-04-17 Well-Controlled Recurrent Pericarditis
• A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting
  2024-512248-47-00 9 2026-04-15 Non-small Cell Lung Cancer (NSCLC)
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia

Showing 49–72 of 905 trials